leisure time -WSS

leisure time

author：hotspot 2025-09-30 18:58:44 - browse：438

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Having children helps parents live longer, especially after age 80

WSS

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Why Eli Lilly’s earnings didn’t quite live up to the hype

Morgan Health, with ambitious aims, wants you to know it’s still here

A single drug, study failures leave Anavex with nothing but cash

Goldman Sachs launches $650M fund for life science investments

Here’s what’s in the FDA plan to include pregnant women in clinical trials

explore

leisure time

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Study gives hint on South Asians’ higher risk of cardiovascular disease

Peter Hotez and the public health issue of online harassment

White House finalizes ITC's import ban of latest Apple Watches

What does generative AI mean for health care? We asked experts

Chronically ill young patients struggle to find fertility info

ChatGPT in medicine: STAT answers readers' burning questions

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

United colonoscopy coverage change 'may cost lives,' doctors say

Abbott's new heart device gets FDA advisory panel nod

focus

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Abbott's new heart device gets FDA advisory panel nod

Websites selling Wegovy, Zepbound ingredients targeted by FDA

The biotech scorecard for Q1: 17 stock

3 medical device trends to watch in 2024

focus

hotspot

Wikipedia

knowledge